Method of treating lower urinary tract symptoms with fexapotide triflutate
US2020360464A1
Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating luts
US2020360466A1
Method of improving lower urinary tract symptoms
US2020061150A1
Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US2019298731A1
Method of treating benign prostatic hyperlasia with antibiotics
US2018250355A1
Compositions and methods for improving sexual function
US2018064785A1
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US2018028597A1
Method of preventing or reducing the incidence of acute urinary retention
US2017360885A1
Method of preventing or reducing the progression of prostate cancer
US2017020957A1
Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US2016361380A1
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US2015148303A1
Peptides effective in the treatment of conditions requiring the removal or destruction of cells
BRPI0708737A2
Method of preventing or reducing cancer risk or incidence by using protein-based peptides in the neural chain
CN101389760A
Peptides effective in the treatment of tumors and other peptides requiring the removal or destruction of cells
US2006188935A1
Protein and its use in diagnosing Alzheimer's disease
US7514407B2
Spheron component peptides and pharmaceutical compositions
NZ535275A
Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
EP1714979A2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
